+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Drugs Market Research Reports

ALK Positive Non-Small Cell Lung Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

ALK Positive Non-Small Cell Lung Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 60 Pages
  • Global
From
EGFR Non-Small Cell Lung Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

EGFR Non-Small Cell Lung Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 80 Pages
  • Global
From
Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 60 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Lung Adenocarcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Lung Adenocarcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 90 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2024 - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy. The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments. In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more